News

• Keratin 18 in NAFLD clinical trials

• – What is NAFLD and what is the role of K18 in NAFLD?
• – What are the main challenges in todays NAFLD clinical trials?
• – How can the VLVbio K18 assays aid in pre-screening subjects
  for inclusion in the trials?
• – How can the VLVbio K18 assays be used as an end-point in the trials?

Click here to access the full broschure!

• M30 Apoptosense® ELISA in paediatric NAFLD

• – What is paediatric NAFLD and what is the role of K18 in NAFLD?
• – How can M30® aid in detecting NASH in children?
• – How can M30® be incorporated into screening of patients with
  childhood obesity to identify metabolic complications?

Click here to access the full broschure!

• The full VLVbio K18 assays including the PEVIVA product line!

• – M30 Apoptosense® ELISA
• – M65® ELISA
• – M65 EpiDeath® ELISA
• – M30 CytoDeath™ ELISA
• – M65 EpiRat™ ELISA

Click here to access the full Product Line!

MEDICA 2021 – Live in Düsseldorf!

Meet us at the MEDICA fair in Düsseldorf this November!

MEDICA is the world’s leading medical trade fair with thousands of visitors every year and we are happy to know that this year will be a live in-person fair again! We are very much looking forward to finally meeting our friends, colleagues, collaborators and all other stakeholders in the field. If you are also attending the fair, do not hesitate to reach out to us to book in a meeting. Looking forward to seeing you all there!

Click here to find our contact information!

VLVbio are proud to be a part of the 2020 Your Liver Campaign by Health Awareness UK!

Non-alcoholic fatty liver disease (NAFLD) is associated with risks of cancer, transplant and even death, yet few at risk of developing the disease are aware of the implications.

“The prevalence of NAFLD has increased significantly in industrialized countries in recent decades and is now at a high level globally. This is related to the so-called Western lifestyle; fast food, lifestyle changes and reduced physical activity” says Prof. Dr. Ali Canbay.

To help fight this silent disease, using non invasive biomarkers is of utmost importance. Dr Slavica Brnjic, CEO at VLVbio says:

“One of the pressing needs in the field is to implement non-invasive and low-cost techniques for diagnosing and staging NASH. Our work at VLVbio is to spread information on the disease as well as increase the acceptance and adoption of non-invasive diagnostic techniques.”

To give rise to awareness on this global disease, we recently worked with Health Awareness on the 2020 Your Liver campaign. A printed publication was enclosed within every copy of the Guardian newspaper and the content is available online, click the link below! The campaign featured exclusive content from key thought leaders and industry voices about the various liver conditions, treatment options and the importance of early diagnosis.

Click here to read the whole piece

The coronavirus-2 (SARS-CoV-2) is currently a public health crisis all over the world with a fatal rate between 2-6 %, and mostly affecting our elderly and people with underlying risk factors such as diabetes, heart disease and hypertension. New research shows that hepatic dysfunction has been seen in 14-53 % of the covid-19 patients, and acute liver injury is associated with higher mortality. The liver injury in covid-19 patients could be a result of the changes in the host cells caused by the viral invasion (cytopathic effect), sepsis or drug-induced liver injury¹.

M30 Apoptosense® ELISA and M65 EpiDeath® ELISA are prognostic biomarkers at ICU admission and for drug-induced liver injury progression

For research use only in USA and Canada.

M30 Apoptosense® ELISA is correlated with biomarkers of inflammation, renal- and liver failure in critically ill patients. A study performed by Koch et al., demonstrates that patients at the ICU that later died had higher levels of serum M30® at admission in comparison to patients that survived. Patients with M30® values >250,8 U/L displayed an excessive short-term mortality².

The PEVIVA® Keratin 18 biomarkers have also been recommended for assessing and anticipating the risk of progression in severe drug-induced liver injury patients in clinical trials, and the biomarkers are strongly associated with liver related death or transplantation within six months of drug-induced liver injury onset³.

The PEVIVA® Keratin 18 biomarkers are the ideal tools for disease monitoring and prognosis in research- and clinical use in critically ill covid-19 patients.

Covid-19 IgM/IgG Rapid Tests

During the current covid-19 pandemic, a lot of focus and energy has been put into testing people for the new corona virus and thus tracking and managing the spread of infection in society. VLVbio has therefore chosen to include a rapid test for Covid-19 IgM and IgG antibodies in our product portfolio. The antibody test we offer is a POC test that within 10 minutes gives a reliable answer if the patient has IgM and / or IgG antibodies to the new coronavirus. The test has been studied extensively in previous research, including a study where the Danish Statens Serum Institut (SSI), examined and validated the test⁴. The rapid test has been shown to have a high sensitivity of up to 96% and a specificity of up to 100% from various studies performed on a total of 857 patients, making it one of the best performing tests available today. The test also does not show any cross-reactivity with other common viruses.

The test, 2019-nCoV IgM / IgG Rapid Test, is imported from the Swiss international distributor TECOmedical AG, where development and production takes place at Dynamiker Biotechnology Co. together with the Chinese Institute of Medical Biology.

The test is of course CE-IVD marked, and has been shown to have similar or even more sensitive test performance than the antibody tests used in the clinical labs for covid-19 today.

Please contact us for more references and quotation.

References

1. Jothimani et al, 2020, COVID-19 and the liver. DOI: https://doi.org/10.1016/j.jhep.2020.06.006
2. Koch et al, High circulating caspase-cleaved keratin 18 fragments (M30) indicate short-term mortality in critically ill patients. DOI: https://doi.org/10.1155/2018/8583121
3. The Drug induced liver injury work package of Innovative Medicines Initiative SAFE-T Consortium and The Hepatotoxicity Working Group of Critical Path Institutes PSTC.
4. Lassaunière et al, Evaluation of nine commercial SARS-CoV-2 immunoassays. DOI: https://doi.org/10.1101/2020.04.09.20056325